Humacyte

What Humacyte does

Humacyte Global, Inc. is a commercial-stage biotechnology company founded in 2004 and headquartered in Durham, North Carolina, that develops universally implantable, off-the-shelf regenerative human tissues for vascular and other applications. The company's core technology is a proprietary bioengineering platform that transforms human vascular cells from cell banks into Acellular Tissue Engineered Vessels (ATEVs) using a novel bioreactor system with biomechanical stress conditioning and a decellularization process that retains key extracellular matrix proteins while removing cells. The resulting bioengineered tissues are designed to become the patient's own living tissue over time through recellularization. Symvess (acellular tissue engineered vessel-tyod) received FDA Biologics License Application approval in December 2024 for extremity vascular trauma repair in adults when autologous vein graft is not feasible, making it the only FDA-approved human-derived bioengineered blood vessel on the U.S. market; commercial shipment began in 2025.

Humacyte operates across a pipeline spanning multiple indications: vascular trauma (commercial), hemodialysis AV access (Phase 3 V012 positive interim results, supplemental BLA planned H2 2026), peripheral artery disease (Phase 2 complete, RMAT designation), coronary artery bypass grafting (CTEV human study initiated November 2025), pediatric heart surgery, Type 1 diabetes via the BioVascular Pancreas, and preclinical programs in lung, urinary conduit, tracheal, and esophageal replacement. The platform holds Regenerative Medicine Advanced Therapy (RMAT) designation across three indications. Clinical evidence includes Phase 3 V012 superiority results showing 91 additional catheter-free days versus AV fistula (p=0.00070), five-year durability data demonstrating structural integrity with smooth muscle cell repopulation, and a humanitarian Ukraine program showing 100% survival in 16 patients.

Humacyte monetizes primarily through one-time hospital sales of Symvess (29 units generating $500K in Q1 2026; $2.0 million full-year 2025 product revenue) plus low-single-digit royalties from Fresenius Medical Care on ex-U.S. net sales, government funding (DoD FY2026 appropriations), and debt financing. The go-to-market combines direct enterprise sales targeting U.S. hospitals via Value Analysis Committee approvals (27 hospitals to date), government channels including the VA Strategic Acquisition Center (170 VA hospitals) and the Defense Logistics Agency Electronic Catalog, a U.S. distribution partnership with Fresenius Medical Care, and emerging international channels in Saudi Arabia (negotiating a JV with $1.475M committed) and Israel (marketing application under review). The company is publicly traded on Nasdaq (HUMA) following its August 2021 business combination with Alpha Healthcare Acquisition Corp. and has raised substantial capital through multiple public offerings, registered direct offerings, and a $77.5M Avenue Capital credit facility.

Name

Humacyte

Legal name

Humacyte Global, Inc.

Website

https://humacyte.com

Company type

Public

Founded year

2004

Operating status

Operating

Headcount range

101–250 employees

Short description

Humacyte is a commercial-stage biotechnology company that develops bioengineered human acellular vessels and tissue constructs. It manufactures and sells Symvess, the only FDA-approved human-derived bioengineered blood vessel, to hospitals, the VA, and the DoD for extremity vascular trauma, with a pipeline in dialysis, PAD, CABG, and Type 1 diabetes.

Ownership category

akta.pro rank

Product category

Regenerative Medicine / Bioengineered Vascular Tissues

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Cardiovascular & Vascular Regeneration (vascular grafts, angiogenesis) (HLAAAGAJ)

akta.pro secondary industry

Vascular Access Devices (AV Grafts, Catheters, Fistula Accessories) (HLAHAKAE)

Keywords

• Regenerative medicine
• Bioengineered vascular grafts
• Tissue engineered vessels
• Acellular tissue products
• Vascular trauma repair

Headquarters

HQ city

Morrisville

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Commercial Product Sales (Symvess): One-time sales of FDA-approved Symvess acellular tissue engineered vessel to hospitals, VA medical centers, and international customers. Q4 2025 product sales of approximately $1.4 million and Q1 2026 product sales of $0.5 million (29 units, up from $0.1 million in prior-year quarter); full-year 2025 total revenue of $2.0 million.
2. Licensing Royalties (Fresenius): Under amended distribution agreement, Fresenius Medical Care retains U.S. distribution rights and receives low-single-digit royalties on net sales of Symvess outside the U.S. (Humacyte regained ex-U.S. distribution rights in April 2026).
3. International Purchase Commitments and Future JV Revenue: Secured a $1.475 million minimum purchase commitment from Saudi Arabia for clinical evaluation and outreach; negotiating a joint venture and licensing agreement with a Saudi-based entity for commercialization in KSA. Israel marketing application has been accepted for review.
4. Government Funding and Grants: Received dedicated U.S. Department of Defense funding in the FY2026 Appropriations Act for biologic vascular repair technologies to support military personnel with traumatic vascular injuries, in addition to other government funding programs supporting development.
5. Debt Financing (Credit Facility): Entered into a credit facility of up to $77.5 million with Avenue Capital Group (Avenue Venture Opportunities Fund II), including an initial $40 million tranche used to retire existing debt, providing growth capital for clinical trials and product development.

Pricing tiers

Go-to-market motion4 records

Distribution channels7 records

Marketing channels10 records

Core offering

Humacyte develops and manufactures bioengineered regenerative human tissues, with Symvess (acellular tissue engineered vessel-tyod) as its lead FDA-approved commercial product indicated for extremity vascular trauma repair in adults when autologous vein graft is not feasible. The company's proprietary ATEV platform is also being investigated for hemodialysis AV access, peripheral artery disease, coronary artery bypass grafting, and advanced organ systems including the BioVascular Pancreas for Type 1 diabetes.

Differentiator

Problem solved

Functional benefit

Brands

• Symvess: FDA-approved acellular tissue engineered vessel (ATEV) product for extremity vascular trauma in adults when urgent revascularization is needed and autologous vein graft is not feasible.
• ATEV (Acellular Tissue Engineered Vessel)
• BioVascular Pancreas (BVP)

Products and services

• Symvess (acellular tissue engineered vessel-tyod) Humacyte's first FDA-approved product, indicated for adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss and autologous vein graft is not feasible. It is the only FDA-approved human-derived bioengineered blood vessel on the market. Sold to hospitals and government healthcare systems on a per-unit basis.
• ATEV (Acellular Tissue Engineered Vessel) Platform Foundational investigational Acellular Tissue Engineered Vessel platform underlying Symvess. Designed as a universally implantable, off-the-shelf, regenerative vascular conduit investigated across multiple clinical applications including arteriovenous access for hemodialysis, peripheral artery disease (PAD), coronary artery bypass grafting (CABG), and pediatric heart surgery.
• BioVascular Pancreas (BVP) Investigational product created by coating pancreatic islets onto the outer surface of the Acellular Tissue Engineered Vessel (ATEV). Being investigated to normalize glucose levels in patients with Type 1 diabetes by providing oxygen and nutrients to islets once implanted into the vasculature.
• Humacyte Lung Program Preclinical program investigating bioengineered lung tissue as a potential treatment for end-stage lung disease, addressing limited lung transplant donors and risk of transplant rejection.
• Urinary Conduit Investigational tissue-engineered urinary conduit being developed as an alternative to using small intestine segments for urinary diversion following bladder removal. Currently in preclinical development.
• Tracheal Replacement Investigational program developing tracheal replacement alternatives for severe airway damage caused by cancer, infection, prolonged intubation, or birth defects. Currently in preclinical development.
• Esophageal Replacement Investigational program developing esophageal replacement alternatives for severely damaged or diseased esophagus. Currently in preclinical development.
• ATEV for Dialysis (AV Access) Investigational use of the ATEV as an alternative to autologous arteriovenous fistula or ePTFE graft for hemodialysis vascular access in patients with end-stage renal disease. Phase 3 V012 trial completed with positive interim results in female patients; supplemental BLA filing planned for H2 2026.
• ATEV for Peripheral Artery Disease (PAD) Investigational use of the 6mm ATEV for arterial bypass procedures in peripheral artery disease patients when saphenous vein is not available. Two Phase 2 human trials completed; the program has received FDA RMAT designation.
• ATEV for Coronary Artery Bypass Grafting (CTEV) Investigational use of the smaller-diameter 3.5mm ATEV in coronary artery bypass grafting (CABG) procedures when saphenous vein grafts are unavailable or unsuitable. Currently in preclinical/early human studies; CTEV human study initiated in November 2025.

Quantifiable outcome

• Phase 3 V012 trial: 220 catheter-free days for ATEV vs 129 days for AV fistula (91-day difference, p=0.00070)
• +5 more outcomes

Named customers6 records

Segments7 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Five partnerships are on record, tiered flagship and core.

• U.S. Department of Veterans Affairs (VA) Strategic Acquisition CenterflagshipChannel Partner/ Reseller/ Distributor · 20 May 2026Symvess added to the VA Strategic Acquisition Center (SAC SING) contract, making it accessible to 170 VA hospitals through a streamlined procurement process. The SAC SING contract requires intensive product and value analysis vetting by a surgical committee before individual hospitals can purchase the product. The company anticipates the SAC contract will expedite its ability to respond to interest from VA surgeons.
• Fresenius Medical CareflagshipChannel Partner/ Reseller/ Distributor · 1 April 2026Fresenius Medical Care holds U.S. distribution rights for Symvess. In April 2026, the agreement was amended so that Humacyte regained exclusive rights to distribute Symvess outside the U.S. while Fresenius receives low-single-digit royalties on net sales outside the U.S. The restructuring enables Humacyte to pursue international expansion and engage prospective corporate partners for international and indication-specific rights. Existing U.S. distribution terms remain unchanged.
• Saudi Arabia-based Entity (JV partner, in negotiation)flagshipStrategic or Co-development Partner · 19 March 2026Humacyte received a $1.475 million minimum purchase commitment for Symvess clinical evaluation and outreach in the Kingdom of Saudi Arabia. The company plans to negotiate a joint venture and license agreement for commercialization of Symvess in KSA, with discussions expected to conclude by July 2, 2026. Represents a key international expansion initiative following the regained ex-U.S. distribution rights.
• U.S. Department of DefenseflagshipStrategic or Co-development Partner · 9 February 2026FY2026 U.S. Department of Defense Appropriations Act included dedicated funding to support evaluation and incorporation of Humacyte's FDA-approved bioengineered vascular repair technology (Symvess) for military personnel with traumatic vascular injuries, following a directive in the FY2026 National Defense Authorization Act enacted in December 2025. Represents the first-ever federal investment in FDA-approved biologic vascular repair technologies.
• Trestle BiotherapeuticscoreStrategic or Co-development Partner · 6 March 2025Trestle Biotherapeutics announced a research collaboration with Humacyte to explore technology synergies combining Trestle's bioengineered kidney tissues with Humacyte's FDA-approved acellular tissue engineered vessel (ATEV) technology, with the goal of creating a vascularized bioengineered kidney. The collaboration aims to address the organ shortage affecting approximately 100,000 U.S. patients on transplant waiting lists and over 600,000 patients dependent on dialysis. Dr. Niklason (Humacyte CEO) serves on Trestle's advisory board.

Scale indicators14 records

Recent moves8 records

Expansion highlights8 records

Direct peers

• Artivion (formerly CryoLife): Artivion is a cardiovascular tissue and device company that produces surgical vascular and cardiac products, including cryopreserved tissues and vascular grafts. It directly overlaps with Humacyte's vascular conduit business and competes for similar vascular surgery hospital customers.
• LeMaitre Vascular: LeMaitre Vascular manufactures and sells vascular grafts, patches, and carotid shunts used by vascular surgeons — the same physician specialty targeted by Humacyte. It is a direct competitor in vascular conduit products sold to hospitals.
• W. L. Gore & Associates (Gore Medical): Gore Medical manufactures ePTFE vascular grafts (including the GORE-TEX Vascular Graft) that compete directly with Symvess as off-the-shelf vascular conduits. As the dominant synthetic vascular graft franchise, it represents the principal competitive threat to Humacyte's trauma indication.

Emerging players

• Xeltis: Xeltis is a clinical-stage European medtech developing bioengineered, restorative cardiovascular vessels using a polymer-based approach. It is an emerging direct competitor in regenerative vascular grafts with overlapping future indications.

Broad incumbents

• Organogenesis Holdings: Organogenesis is a commercial-stage regenerative medicine company selling bioengineered skin and wound-care products. As a public peer in regenerative human tissue, it offers a comparable commercial-stage business model and regulatory pathway reference for Humacyte.
• Vericel Corporation: Vericel is a commercial-stage regenerative medicine company selling autologous cell therapies (MACI for cartilage, Epicel for burns). Comparable as a small-cap public commercial regenerative medicine peer serving surgical specialists via hospital channels.
• MiMedx Group: MiMedx develops and commercializes regenerative human amniotic tissue products for wound care and surgical recovery. Like Humacyte, it is a public regenerative medicine peer with hospital-channel sales, FDA-registered biologics, and similar commercial-stage dynamics.
• Terumo (Terumo Aortic / Vascutek): Terumo manufactures vascular grafts (woven, knitted, ePTFE) through its Terumo Aortic business, serving the same vascular surgery customer base as Humacyte. A broad incumbent in vascular conduits with global hospital distribution.
• Medtronic (Vascular & Aortic): Medtronic is a global leader in cardiovascular devices including vascular grafts and endovascular products. Its breadth of vascular portfolio and hospital relationships represent both a major competitive incumbent and a potential strategic acquirer for Humacyte.

Others

• Fresenius Medical Care: Fresenius Medical Care is a leading global dialysis provider and Humacyte's existing U.S. distribution partner for Symvess. While not a product peer, it is the most relevant ecosystem partner given its end-customer relationships with U.S. hemodialysis centers that represent Humacyte's largest future indication.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/humacyte
• Facebookfacebook.com/257740747668577
• LinkedInlinkedin.com/company/humacyte

Revenue estimate

Valuation estimate

Number of profiles

Profiles23 records

Subsidiaries1 record

Funding overview

Funding rounds17 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Humacyte